Cue Biopharma (CUE) News Today $0.59 -0.04 (-6.35%) (As of 09/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 3, 2024 | finance.yahoo.comCue Biopharma to Present at The Promise of Interleukin-2 Therapy ConferenceAugust 20, 2024 | ca.finance.yahoo.comQ2 2024 Cue Biopharma Inc Earnings CallAugust 20, 2024 | markets.businessinsider.comCue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 20, 2024 | msn.comCue Biopharma, Inc. (NASDAQ:CUE) Q2 2024 Earnings Call TranscriptAugust 19, 2024 | globenewswire.comCue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsJuly 26, 2024 | bizjournals.comCuts at Cue Biopharma include CEO salary, 25% of jobsJuly 26, 2024 | markets.businessinsider.comCue Biopharma Receives ‘Buy’ Rating Amid Strategic Shift and Promising Autoimmune Therapeutics PipelineJuly 26, 2024 | finance.yahoo.comCue Biopharma downsizes to focus on autoimmune pipelineJuly 25, 2024 | uk.finance.yahoo.comApplied Intuition raises $300M four months after raising $250MJuly 25, 2024 | finance.yahoo.comCue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital RequirementsJune 2, 2024 | marketbeat.comCue Biopharma, Inc. (NASDAQ:CUE) Sees Significant Decrease in Short InterestCue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) was the target of a large decline in short interest in May. As of May 15th, there was short interest totalling 4,590,000 shares, a decline of 7.5% from the April 30th total of 4,960,000 shares. Based on an average daily volume of 295,700 shares, the short-interest ratio is currently 15.5 days.May 30, 2024 | investorplace.comMedical Moonshots: 3 Biotech Stocks Set to SkyrocketMay 16, 2024 | markets.businessinsider.comCue Biopharma’s Promising Future: A Comprehensive Buy Rating JustificationMay 11, 2024 | finance.yahoo.comCue Biopharma First Quarter 2024 Earnings: Beats ExpectationsMay 10, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE)May 10, 2024 | investorplace.comCUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | finance.yahoo.comCue Biopharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 9, 2024 | finance.yahoo.comCue Biopharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 8, 2024 | globenewswire.comCue Biopharma to Present at the 20th Annual PEGS Boston SummitMay 7, 2024 | finance.yahoo.comCue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences ConferenceApril 24, 2024 | globenewswire.comCue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 9, 2024 | markets.businessinsider.comForecasting The Future: 4 Analyst Projections For Cue BiopharmaApril 9, 2024 | marketbeat.comStifel Nicolaus Reiterates "Buy" Rating for Cue Biopharma (NASDAQ:CUE)Stifel Nicolaus reiterated a "buy" rating and set a $8.00 price objective on shares of Cue Biopharma in a research report on Tuesday.April 9, 2024 | finanznachrichten.deCue Biopharma, Inc.: Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business HighlightsApril 9, 2024 | finance.yahoo.comCue Biopharma Inc (CUE) Q4 2023 Earnings Call Transcript Highlights: Strategic Alliances and ...April 8, 2024 | markets.businessinsider.comCue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business HighlightsApril 8, 2024 | globenewswire.comCue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business HighlightsApril 8, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, April 08, 2024April 7, 2024 | markets.businessinsider.comCue Biopharma is about to announce earnings — here's what Wall Street expectsApril 3, 2024 | marketbeat.comCue Biopharma (NASDAQ:CUE) Receives Overweight Rating from Piper SandlerPiper Sandler restated an "overweight" rating and set a $8.00 price objective on shares of Cue Biopharma in a research report on Wednesday.April 2, 2024 | investorplace.comCUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023April 2, 2024 | finance.yahoo.comCue Biopharma to Host Business Update Call and WebcastApril 2, 2024 | finance.yahoo.comCue Biopharma to Host Business Update Call and WebcastApril 1, 2024 | msn.comCarisma to cut 37% of workforce, stock falls 8%March 18, 2024 | marketbeat.comCue Biopharma (CUE) to Release Quarterly Earnings on TuesdayCue Biopharma (NASDAQ:CUE) will be releasing earnings on Tuesday, March 19, Yahoo Finance reports.March 13, 2024 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Silence TherapeuticsMarch 13, 2024 | marketbeat.comCue Biopharma (NASDAQ:CUE) Coverage Initiated at Jefferies Financial GroupJefferies Financial Group initiated coverage on Cue Biopharma in a report on Wednesday. They set a "buy" rating and a $6.00 price target on the stock.February 29, 2024 | finance.yahoo.comCue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers SymposiumFebruary 29, 2024 | globenewswire.comCue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers SymposiumFebruary 27, 2024 | morningstar.comCue Biopharma Inc Ordinary SharesFebruary 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE)February 6, 2024 | finance.yahoo.comCue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 6, 2024 | finance.yahoo.comCue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 1, 2024 | marketbeat.comCue Biopharma, Inc. (NASDAQ:CUE) Short Interest Up 6.7% in JanuaryCue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) was the target of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 3,650,000 shares, an increase of 6.7% from the December 31st total of 3,420,000 shares. Based on an average daily volume of 361,500 shares, the short-interest ratio is currently 10.1 days.January 17, 2024 | finance.yahoo.comCue Biopharma (NASDAQ:CUE) investors are sitting on a loss of 80% if they invested three years agoJanuary 16, 2024 | marketbeat.comShort Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Expands By 5.2%Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,420,000 shares, an increase of 5.2% from the December 15th total of 3,250,000 shares. Based on an average daily trading volume, of 362,400 shares, the short-interest ratio is currently 9.4 days.January 3, 2024 | marketbeat.comShort Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Rises By 8.3%Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 3,250,000 shares, a growth of 8.3% from the November 30th total of 3,000,000 shares. Based on an average trading volume of 341,700 shares, the days-to-cover ratio is presently 9.5 days.December 14, 2023 | investorplace.comCUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023December 7, 2023 | finance.yahoo.comAre Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?November 22, 2023 | finance.yahoo.comCue Biopharma to Present at the JMP Securities Hematology and Oncology Summit Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address China Stockpiling Gold “Like No Tomorrow” (Ad)For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . Click here now to get your free 'De-Dollarization' Guide. CUE Media Mentions By Week CUE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CUE News Sentiment▼0.640.55▲Average Medical News Sentiment CUE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CUE Articles This Week▼11▲CUE Articles Average Week Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Kodiak Sciences News Cadrenal Therapeutics News Cellectis News Immunic News Nuvectis Pharma News Repare Therapeutics News Atyr PHARMA News Inventiva News INmune Bio News Senti Biosciences News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CUE) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
